(Q44567973)

English

Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V).

scientific article published in September 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V). (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

0 references

thromboembolism

1 reference

based on heuristic

inferred from title

atrial fibrillation

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Jonathan L. Halperin

1

object named as

Jonathan L Halperin

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

author name string

Executive Steering Committee, SPORTIF III and V Study Investigators

2

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

language of work or name

0 references

publication date

1 September 2003

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

American Heart Journal

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

146

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

431-438

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Antithrombotic therapy in atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900325-9

7 January 2021

Embolic complications in paroxysmal atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900325-9

7 January 2021

Antithrombotic and thrombolytic therapy for ischemic stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900325-9

7 January 2021

Antithrombotic therapy in atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900325-9

7 January 2021

Atrial fibrillation as an independent risk factor for stroke: the Framingham Study

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900325-9

7 January 2021

ABC of atrial fibrillation. History, epidemiology, and importance of atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900325-9

7 January 2021

Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900325-9

7 January 2021

Stroke Prevention in Atrial Fibrillation Study. Final results

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900325-9

7 January 2021

The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900325-9

7 January 2021

Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900325-9

7 January 2021

Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900325-9

7 January 2021

Oral anticoagulation in nonvalvular atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900325-9

7 January 2021

Management of atrial fibrillation: discrepancy between guideline recommendations and actual practice exposes patients to risk for complications

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900325-9

7 January 2021

Prevalence of atrial fibrillation and eligibility for anticoagulants in the community.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900325-9

7 January 2021

Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900325-9

7 January 2021

Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900325-9

7 January 2021

Ximelagatran, an oral direct thrombin inhibitor, has a low potential for cytochrome P450-mediated drug-drug interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900325-9

7 January 2021

Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900325-9

7 January 2021

Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900325-9

7 January 2021

Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900325-9

7 January 2021

Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding, tolerability, and safety study

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900325-9

7 January 2021

ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Co

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900325-9

7 January 2021

Use of the Barthel index and modified Rankin scale in acute stroke trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900325-9

7 January 2021

Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: ethical and scientific issues

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900325-9

7 January 2021

Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 2: practical issues and specific cases.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900325-9

7 January 2021

Active-control clinical trials to establish equivalence or noninferiority: methodological and statistical concepts linked to quality

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900325-9

7 January 2021

Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900325-9

7 January 2021

Identifiers

10.1016/S0002-8703(03)00325-9

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44567973&oldid=2131995672"